Results 1 to 10 of about 10,241 (240)

GLP-1RA and the possible skin aging [PDF]

Endocrine
Abstract “Ozempic face” and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic inflammation and possibly promote skin health.
Stavroula A Paschou, Konstantinos I Tsamis, Theodora Psaltopoulou   +2 more
exaly   +5 more sources

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD. [PDF]

Kidney Int Rep
Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of 2 clinical trials.
Singh AK, Anker SD, Pitt B, Rossing P, Ruilope LM, Ahlers C, Farag YMK, Lambelet M, Brinker MD, Rohwedder K, Filippatos G, FIDELIO-DKD and FIGARO-DKD Investigators.   +11 more
europepmc   +5 more sources

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies [PDF]

Metabolites, 2022
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits.
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino   +6 more
doaj   +3 more sources

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

Frontiers in Pharmacology, 2022
Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular benefits, but the relationship between GLP-1RA and tumors is controversial.
Yuhuan Lv, Meng Yu, Mei Mei
exaly   +3 more sources

The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. [PDF]

J Eur Acad Dermatol Venereol
Abstract Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP‐1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction.
Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ.   +5 more
europepmc   +5 more sources

GLP-1RA Use and Thyroid Cancer Risk.

JAMA Otolaryngol Head Neck Surg
ImportanceThe increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RA) demands a better understanding of their association with thyroid cancer.ObjectiveTo estimate the risk of incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1RA vs other common glucose-lowering medications.Design, Setting, and ...
Brito JP, Herrin J, Swarna KS, Singh Ospina NM, Montori VM, Toro-Tobon D, Umpierrez GE, Galindo RJ, Deng Y, Mickelson MM, Shao H, Polley EC, McCoy RG.   +12 more
europepmc   +3 more sources

GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI

Frontiers in Endocrinology
BackgroundGlucagon-like peptide-1 receptor agonist(GLP-1RA) is commonly used in patients with cardiovascular disease due to its significant improvement in the prognosis of atherosclerotic cardiovascular disease (ASCVD).
Ling Xu, Dan Zhu
exaly   +3 more sources

GLP-1RA Medications Significantly Reduce Fracture Risk in the Diabetic Foot and Ankle Patient Population [PDF]

Foot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Diabetes mellitus (DM) is associated with an elevated risk for sustaining a fracture, driven by both direct and indirect ...
Samantha Olson BS, Alexandra Vaughan-Masamitsu BS, Michael Levidy MD, Lincoln Dutcher MD, Jana Davis MD   +4 more
doaj   +2 more sources

Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity [PDF]

Diabetes Therapy
Introduction People with type 2 diabetes are at heightened risk for severe outcomes related to COVID-19 infection, including hospitalization, intensive care unit admission, and mortality.
Klara R Klein, Trine Abrahamsen, Anna R Kahkoska   +2 more
exaly   +3 more sources

Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study [PDF]

Sex differences may influence pathophysiology, treatment response, and outcomes of type 2 diabetes (T2D). We assessed whether sex affected clinical response to GLP-1 receptor agonists (GLP-1RA) in a large real-world cohort.
Avogaro A., Cignarella A., Consoli A., Fadini G. P., Leonetti F., Marassi M., Marzullo P., Nollino L., Russo G. T., Strazzabosco M.   +9 more
core   +2 more sources